GNRH1 and endometriosis: Elagolix, an oral GnRH antagonist, has been approved by the US Food and Drug administration (FDA) to treat moderate to severe pain associated with endometriosis and is currently being developed to treat severe menstrual bleeding associated with hysteromyoma (Archer et al., 2017; Diamond et al., 2017; Taylor et al., 2017; Surrey et al., 2018; Schiffman et al., 2020; Schlaff et al., 2020).